Results 11 to 20 of about 10,848 (199)

Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study [PDF]

Haematologica, 2018
The safety of obinutuzumab, alone or with chemotherapy, was studied in a non-randomized, open-label, non-comparative, phase IIIb study (GREEN) in previously untreated or relapsed/refractory chronic lymphocytic leukemia.
Véronique Leblond, Melih Aktan, Christelle M. Ferra Coll, Caroline Dartigeas, Jens Kisro, Marco Montillo, João Raposo, Jean-Louis Merot, Susan Robson, Ekaterina Gresko, Francesc Bosch, Stephan Stilgenbauer, Robin Foà   +12 more
doaj   +3 more sources

The B cell death function of obinutuzumab-HDEL produced in plant (Nicotiana benthamiana L.) is equivalent to obinutuzumab produced in CHO cells. [PDF]

PLoS ONE, 2018
Plants have attracted attention as bio-drug production platforms because of their economical and safety benefits. The preliminary efficacy of ZMapp, a cocktail of antibodies produced in N.
Jin Won Lee, Woon Heo, Jinu Lee, Narae Jin, Sei Mee Yoon, Ki Youl Park, Eun Yu Kim, Woo Taek Kim, Joo Young Kim   +8 more
doaj   +5 more sources

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial [PDF]

Haematologica, 2022
iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Carol Moreno, Richard Greil, Fatih Demirkan, Alessandra Tedeschi, Bertrand Anz, Loree Larratt, Martin Simkovic, Jan Novak, Vladimir Strugov, Devinder Gill, John G. Gribben, Kevin Kwei, Sandra Dai, Emily Hsu, James P. Dean, Ian W. Flinn   +15 more
doaj   +2 more sources

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

Blood
Key Points • First-line acalabrutinib-obinutuzumab resulted in significantly higher PFS and OS than chemoimmunotherapy regardless of high-risk features.• Acalabrutinib-obinutuzumab resulted in improved PFS rates vs acalabrutinib monotherapy in a post hoc
Jeff P. Sharman, M. Egyed, W. Jurczak, A. Skarbnik, Krish Patel, I. Flinn, M. Kamdar, T. Munir, R. Walewska, M. Hughes, L. Fogliato, Y. Herishanu, V. Banerji, G. Follows, Patricia A. Walker, P. Ghia, A. Janssens, John C. Byrd, E. Ferrant, A. Ferrajoli, W. Wierda, Catherine Wangui Wachira, B. Suterwala, Paulo A. Palhares de Miranda, V. Munugalavadla, Chuan-Chuan Wun, J. Woyach   +26 more
semanticscholar   +2 more sources

Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways [PDF]

iScience, 2021
Summary: The anti-CD20 monoclonal antibodies rituximab and obinutuzumab differ in their mechanisms of action, with obinutuzumab evoking greater direct B cell death.
Jennifer Edelmann, Arran D. Dokal, Emma Vilventhraraja, Karlheinz Holzmann, David Britton, Tetyana Klymenko, Hartmut Döhner, Mark Cragg, Andrejs Braun, Pedro Cutillas, John G. Gribben   +10 more
doaj   +2 more sources

Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab

Hematology/Oncology and Stem Cell Therapy, 2017
Objective/background: Membranoproliferative glomerulonephritis (MPGN) is a common extramedullary renal presentation in chronic lymphocytic leukemia (CLL) and can present with either a frank renal failure or proteinuria.
Punit Jain, Rashmi Kanagal-Shamanna, William Wierda, Alessandra Ferrajoli, Michael Keating, Nitin Jain   +5 more
doaj   +2 more sources

Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study

Frontiers in Immunology
ObjectiveThis study aimed to evaluate the efficacy and safety of obinutuzumab, a novel anti-CD20 monoclonal antibody, in patients with primary membranous nephropathy (pMN).MethodsFifty-five patients with pMN treated with obinutuzumab were respectively ...
Xi Cheng, Zhen-feng Zheng, Yan Qi, Xin Cao, Xi-qian Gao, Ying-xin Fang, Li Wei, Wen-ya Shang, Tie-kun Yan, Jun-ya Jia, Peng-cheng Xu, Qiu-hua Gu   +11 more
doaj   +2 more sources

Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia

SAGE Open Medical Case Reports, 2019
Obinutuzumab is used for the treatment of chronic lymphocytic leukemia. So far there are no data of using this for retreatment in patients who have received it previously.
Sharad Khurana, Salman Ahmed, Victoria R Alegria, Sonikpreet Aulakh, Meghna Ailawadhi, Anshika Singh, Asher Chanan-Khan, Sikander Ailawadhi   +7 more
doaj   +2 more sources

Obinutuzumab-induced acute thrombocytopenia: a case report and literature review [PDF]

Frontiers in Oncology
BackgroundObinutuzumab, a humanized type II anti-CD20 monoclonal antibody, is widely used in the treatment of B-cell lymphomas. Thrombocytopenia typically occurs 1 to 2 weeks after administration.
Xuelin Dou, Kongyang Li, Kongyang Li, Jin Lu   +3 more
doaj   +2 more sources

Obinutuzumab as Initial or Second-Line Therapy in Patients With Primary Membranous Nephropathy

Kidney International Reports
Introduction: B-cell lymphocytes have been demonstrated to play a key role in the pathogenesis underlying membranous nephropathy (MN). The aim of this study was to evaluate the therapeutic efficacy and safety of Obinutuzumab, a glycoengineered type II ...
Xiaole Su, Binxin Wu, Xuan Tie, Xiaojiao Guo, Rongrong Feng, Xi Qiao, Lihua Wang   +6 more
doaj   +2 more sources